Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Rhea-AI Summary

Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2024. The company achieved record quarterly revenue of $181.9 million (up 22% YoY) and full-year revenue of $631.4 million (up 11% YoY). Q4 GAAP net income was $12.5 million with record adjusted EBITDA of $107.7 million.

Key product performance included Jornay PM with Q4 net revenue of $29.3 million and pro forma full-year revenue of $100.7 million, showing 29% YoY prescription growth. Belbuca achieved record quarterly revenue of $55.2 million (up 12% YoY), while Xtampza ER posted record revenue of $51.5 million (up 6% YoY).

The company ended 2024 with $162.8 million in cash and equivalents, after completing the $200 million Ironshore Therapeutics acquisition and executing $60 million in share repurchases.

Positive

• Record Q4 revenue of $181.9M (+22% YoY)
• Full-year revenue growth of 11% to $631.4M
• Jornay PM prescriptions up 29% YoY
• Belbuca revenue up 12% YoY to $55.2M
• Full-year adjusted EBITDA growth of 9% to $401.2M
• Strong cash position of $162.8M

Negative

• Q4 GAAP net income decreased to $12.5M from $31.9M YoY
• Operating expenses increased 83% YoY in Q4
• Cash position declined from $310.5M to $162.8M YoY
• Adjusted operating expenses up 97% in Q4 YoY

Insights

Financial Analyst

Collegium Pharmaceutical delivered record financial results for Q4 and FY 2024, successfully executing its diversification strategy while maintaining strong growth in its core pain portfolio. Q4 revenue reached $181.9 million (+22% YoY) with full-year revenue of $631.4 million (+11% YoY), driven by both organic growth and the strategic Ironshore acquisition.

The company's product diversification is already showing results, with Jornay PM (ADHD medication) contributing $29.3 million in Q4 revenue and $100.7 million pro forma for the full year. The 29% YoY prescription growth for Jornay PM indicates strong market acceptance and positions this product as a significant growth driver, with management projecting $135+ million in 2025 revenue.

Collegium's core pain portfolio continues to perform well despite market challenges, with Belbuca achieving $55.2 million in Q4 revenue (+12% YoY) and Xtampza ER reaching $51.5 million (+6% YoY). These prescription growth rates outpace the broader pain management market.

While Q4 GAAP net income decreased to $12.5 million from $31.9 million in Q4 2023, this primarily reflects the 83% increase in operating expenses related to the Ironshore integration. The company's adjusted EBITDA growth ($107.7 million for Q4, +3% YoY) demonstrates underlying operational strength.

Despite significant capital deployment in 2024 ($200 million for acquisition, $60 million for share repurchases), Collegium maintains financial flexibility with $162.8 million in cash and a net debt to adjusted EBITDA ratio below 2x, positioning them well for additional strategic opportunities while supporting their commercial priorities.

Healthcare Strategy Expert

Collegium's Q4 and full-year 2024 results reveal a strategic transformation from a pain-focused specialty pharma to a more diversified biopharmaceutical company. The Ironshore acquisition represents a calculated pivot into neuropsychiatry, reducing concentration risk while targeting complementary growth markets that leverage the company's commercial infrastructure.

The early commercial success of Jornay PM is particularly noteworthy in the competitive ADHD landscape. The 29% YoY prescription growth significantly outpaces the broader ADHD market's ~4-5% growth rate, suggesting Jornay PM's delayed-release evening dosing formulation is gaining traction as a differentiated treatment option. The projected 34%+ revenue growth for Jornay PM in 2025 ($135+ million) will require continued execution in a market dominated by established players and generics.

While diversifying beyond pain management, Collegium has maintained focus on its core portfolio, with Belbuca and Xtampza ER both achieving record revenues. This balanced approach has allowed for 11% topline growth despite headwinds in the pain management sector, where prescribing patterns remain under regulatory scrutiny.

The 97% increase in adjusted operating expenses reflects the substantial commercial investment required to compete effectively in neuropsychiatry while maintaining momentum in pain management. This dual-therapeutic approach creates operational synergies but provides strategic diversification benefits.

Collegium's capital allocation strategy balances growth investments, debt management, and shareholder returns. With a net debt to EBITDA ratio below 2x, the company maintains flexibility for additional bolt-on acquisitions while continuing share repurchases. The focus on commercial-stage assets rather than early R&D aligns with their strategy of building a portfolio of established, cash-generating products rather than assuming pipeline development risks.

– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million –

– Reported Quarterly Jornay PM^® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million –

– Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million –

– Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million –

– Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million;
Repurchased $60.0 Million in Shares in 2024 –

– Reaffirmed Full-Year 2025 Guidance –

– Conference Call Scheduled for Today at 4:30 p.m. ET –

STOUGHTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter and full year ended December 31, 2024, and provided a business update.

“2024 was a year of strong execution for Collegium, marked by robust performance in our pain portfolio and the addition of Jornay PM, establishing our presence in neuropsychiatry and reaffirming our commitment to helping improve the lives of people living with serious medical conditions. This was made possible thanks to the dedication of our talented team,” said Vikram Karnani, President and Chief Executive Officer. “We drove record financial results in 2024 and are poised for a new phase of growth in 2025 and beyond. We are focused on growing Jornay PM, maximizing our pain portfolio, and strategically deploying capital to create value and continue to build a leading, diversified biopharmaceutical company.”

“We are proud to have delivered on our financial commitments and strategic priorities for 2024, including growing total revenue by 11% and adjusted EBITDA by 9%, generating robust operating cash flows in a year that we completed an acquisition, and deploying capital to expand and diversify our business while executing $60 million in share repurchases,” said Colleen Tupper, Chief Financial Officer. “We are in a position of financial strength, ending the year with net debt to adjusted EBITDA of less than two times. We are committed to creating long-term value for our shareholders by executing on our commercial priorities and strategically deploying capital in a disciplined manner.”

Business Highlights

• Grew Jornay PM prescriptions 29% year-over-year and 11% quarter-over-quarter in the quarter ended December 31, 2024 (the 2024 Quarter). Pro forma Jornay PM net revenue was $100.7 million in 2024 and expected to be in excess of $135 million in 2025.
• Grew Belbuca^® total prescriptions 5.6% year-over-year and 2.9% quarter-over-quarter in the 2024 Quarter. Belbuca net revenue was a record $55.2 million in the 2024 Quarter, up 12% year-over-year.
• Xtampza^® ER net revenue was a record $51.5 million in the 2024 Quarter, up 6% year-over-year.
• Appointed Nancy S. Lurker to Collegium’s Board of Directors, effective February 4, 2025. Ms. Lurker most recently served as President and Chief Executive Officer of EyePoint Pharmaceuticals, Inc. until 2023, when she transitioned to the role of Executive-Vice Chair of its Board of Directors.
• In 2024, repurchased $60.0 million in shares, including $25.0 million repurchased in the fourth quarter of 2024 and $35.0 million repurchased through an accelerated share repurchase program in May 2024.
  

Financial Guidance for 2025

The Company reaffirms its full-year 2025 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:

Product Revenues, Net	$735.0 to $750.0 million
Adjusted Operating Expenses (Excluding Stock-Based Compensation)	$220.0 to $230.0 million
Adjusted EBITDA (Excluding Stock-Based Compensation)	$435.0 to $450.0 million

Financial Results for Quarter Ended December 31, 2024

• Product revenues, net were $181.9 million for the 2024 Quarter, compared to $149.7 million for the quarter ended December 31, 2023 (the 2023 Quarter), representing a 22% increase year-over-year.
• GAAP operating expenses were $60.2 million for the 2024 Quarter, compared to $32.9 million for the 2023 Quarter, representing an 83% increase year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were $51.1 million for the 2024 Quarter, compared to $25.9 million for the 2023 Quarter, representing a 97% increase year-over-year.
• GAAP net income for the 2024 Quarter was $12.5 million, with $0.39 GAAP earnings per share (basic) and $0.36 GAAP earnings per share (diluted), compared to GAAP net income for the 2023 Quarter of $31.9 million, with $0.99 GAAP earnings per share (basic) and $0.82 GAAP earnings per share (diluted). Non-GAAP adjusted net income for the 2024 Quarter was $68.5 million, with $1.75 adjusted earnings per share, compared to non-GAAP adjusted net income for the 2023 Quarter of $64.2 million, with $1.58 adjusted earnings per share.
• Adjusted EBITDA for the 2024 Quarter was $107.7 million, compared to $104.2 million for the 2023 Quarter, representing a 3% increase year-over-year.
• The Company exited the 2024 Quarter with cash, cash equivalents and marketable securities of $162.8 million, down from $310.5 million as of December 31, 2023. During 2024, $200.0 million of cash on hand funded the acquisition of Ironshore Therapeutics and $60.0 million funded share repurchases as part of the Company’s share repurchase program.
  

Financial Results for Year Ended December 31, 2024

• Product revenues, net were $631.4 million for the year ended December 31, 2024 (FY 2024), compared to $566.8 million for the year ended December 31, 2023 (FY 2023), representing an 11% increase year-over-year.
• GAAP operating expenses were $207.4 million for FY 2024, compared to $159.2 million for FY 2023, representing a 30% increase year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were $150.6 million for FY 2024, compared to $123.6 million for FY 2023, representing a 22% increase year-over-year.
• GAAP net income for FY 2024 was $69.2 million, with $2.14 GAAP earnings per share (basic) and $1.86 GAAP earnings per share (diluted), compared to GAAP net income for FY 2023 of $48.2 million, with $1.43 GAAP earnings per share (basic) and $1.29 GAAP earnings per share (diluted). Non-GAAP adjusted net income for FY 2024 was $254.8 million, with $6.45 adjusted earnings per share, compared to non-GAAP adjusted net income for FY 2023 of $223.3 million, with $5.47 adjusted earnings per share.
• Adjusted EBITDA for FY 2024 was $401.2 million, compared to $367.0 million for FY 2023, representing a 9% increase year-over-year.

Conference Call Information

The Company will host a conference call and live audio webcast on Thursday, February 27, 2025, at 4:30 p.m. ET. To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Fourth Quarter and Full-Year 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Non-GAAP Financial Measures

To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management.

We may discuss the following financial measures that are not calculated in accordance with GAAP in our quarterly and annual reports, earnings press releases, and conference calls.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as:

• adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
• adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
• adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes;
• adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
• we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;
• we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
• we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business;
• we exclude litigation settlements from adjusted EBITDA, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred;
• we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, and miscellaneous other acquisition related expenses incurred;
• we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business;
• we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; and
• we exclude other expenses, from time to time, that are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis.

Adjusted Operating Expenses

Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.

Adjusted Net Income and Adjusted Earnings Per Share

Adjusted net income is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude significant income and expense items that are non-cash or not indicative of ongoing operations, including consideration of the tax effect of the adjustments. Adjusted earnings per share is a non-GAAP financial measure that represents adjusted net income per share. Adjusted weighted-average shares - diluted is calculated in accordance with the treasury stock, if-converted, or contingently issuable accounting methods, depending on the nature of the security.

Reconciliations of adjusted EBITDA, adjusted operating expenses, adjusted net income, and adjusted earnings per share to the most directly comparable GAAP financial measures are included in this press release.

The Company has not provided a reconciliation of its full-year 2025 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements. These items are uncertain and depend on various factors that are outside of the Company’s control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA or adjusted operating expenses would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our full-year 2025 financial guidance, including projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to realize the anticipated benefits associated with the acquisition of Ironshore; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency (DEA), compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contacts:
Ian Karp
Vice President, Investor Relations
ir@collegiumpharma.com

Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com

Media Contact:
Cheryl Wheeler
Head of Corporate Communications
communications@collegiumpharma.com

Collegium Pharmaceutical, Inc. Unaudited Selected Consolidated Balance Sheet Information (in thousands)
		December 31,			December 31,
		2024			2023
Cash and cash equivalents		$	70,565		$	238,947
Marketable securities			92,198			71,601
Accounts receivable, net			228,540			179,525
Inventory			35,560			32,332
Prepaid expenses and other current assets			30,394			15,195
Property and equipment, net			14,329			15,983
Operating lease assets			5,822			6,029
Intangible assets, net			891,402			421,708
Restricted cash			26,047			1,047
Deferred tax assets			98,033			26,259
Other noncurrent assets			8,368			825
Goodwill			162,333			133,857
Total assets		$	1,663,591		$	1,143,308
Accounts payable and accrued liabilities			76,058			46,263
Accrued rebates, returns and discounts			338,642			227,331
Business combination consideration payable			28,956			—
Term notes payable			615,316			405,046
Convertible senior notes			237,172			262,125
Operating lease liabilities			6,810			7,112
Deferred royalty obligation			120,613			—
Deferred revenue			10,000			—
Contingent consideration			1,182			—
Shareholders’ equity			228,842			195,431
Total liabilities and shareholders’ equity		$	1,663,591		$	1,143,308

Collegium Pharmaceutical, Inc. Unaudited Condensed Statements of Operations (in thousands, except share and per share amounts)
	Three Months Ended December 31,										Years Ended December 31,
	2024				2023						2024				2023
Product revenues, net	$	181,949			$	149,745					$	631,449			$	566,767
Cost of product revenues
Cost of product revenues (excluding intangible asset amortization)		28,190				20,601						88,801				94,838
Intangible asset amortization and impairment		55,471				34,514						165,304				145,760
Total cost of product revenues		83,661				55,115						254,105				240,598
Gross profit		98,288				94,630						377,344				326,169
Operating expenses
Selling, general and administrative		63,091				32,942						210,363				159,208
Gain on fair value remeasurement of contingent consideration		(2,914	)			—						(2,914	)			—
Total operating expenses		60,177				32,942						207,449				159,208
Income from operations		38,111				61,688						169,895				166,961
Interest expense		(22,654	)			(19,281	)					(73,974	)			(83,339	)
Interest income		1,812				4,303						13,976				15,615
Loss on extinguishment of debt		—				—						(11,329	)			(23,504	)
Income before income taxes		17,269				46,710						98,568				75,733
Provision for income taxes		4,733				14,770						29,378				27,578
Net income	$	12,536			$	31,940					$	69,190			$	48,155
Earnings per share — basic	$	0.39			$	0.99					$	2.14			$	1.43
Weighted-average shares — basic		32,078,621				32,301,211						32,273,850				33,741,213
Earnings per share — diluted	$	0.36			$	0.82					$	1.86			$	1.29
Weighted-average shares — diluted		40,109,649				41,279,981						40,424,180				41,788,125

Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands) (unaudited)
	Three Months Ended December 31,									Years Ended December 31,
	2024				2023					2024				2023
GAAP net income	$	12,536			$	31,940				$	69,190			$	48,155
Adjustments:
Interest expense		22,654				19,281					73,974				83,339
Interest income		(1,812	)			(4,303		)			(13,976	)			(15,615	)
Loss on extinguishment of debt		—				—					11,329				23,504
Provision for income taxes		4,733				14,770					29,378				27,578
Depreciation		1,041				949					3,856				3,496
Amortization		55,471				34,514					165,304				145,760
Stock-based compensation		7,596				7,002					32,400				27,136
Litigation settlements		—				—					—				8,500
Recognition of step-up basis in inventory		3,968				—					5,269				15,116
CEO transition expense		—				—					3,051				—
Acquisition related expenses		4,443				—					24,329				—
Gain on fair value remeasurement of contingent consideration		(2,914	)			—					(2,914	)			—
Total adjustments	$	95,180			$	72,213				$	332,000			$	318,814
Adjusted EBITDA	$	107,716			$	104,153				$	401,190			$	366,969

Collegium Pharmaceutical, Inc. Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands) (unaudited)
	Three Months Ended December 31,							Years Ended December 31,
	2024				2023			2024				2023
GAAP operating expenses	$	60,177			$	32,942		$	207,449			$	159,208
Adjustments:
Stock-based compensation		7,596				7,002			32,400				27,136
Litigation settlements		—				—			—				8,500
CEO transition expense		—				—			3,051				—
Acquisition related expenses		4,443				—			24,329				—
Gain on fair value remeasurement of contingent consideration		(2,914	)			—			(2,914	)			—
Total adjustments	$	9,125			$	7,002		$	56,866			$	35,636
Adjusted operating expenses	$	51,052			$	25,940		$	150,583			$	123,572

Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts) (unaudited)
	Three Months Ended December 31,								Years Ended December 31,
	2024				2023				2024				2023
GAAP net income	$	12,536			$	31,940			$	69,190			$	48,155
Adjustments:
Non-cash interest expense		4,664				1,963				9,729				8,635
Loss on extinguishment of debt		—				—				11,329				23,504
Amortization		55,471				34,514				165,304				145,760
Stock-based compensation		7,596				7,002				32,400				27,136
Litigation settlements		—				—				—				8,500
Recognition of step-up basis in inventory		3,968				—				5,269				15,116
CEO transition expense		—				—				3,051				—
Acquisition related expenses		4,443				—				24,329				—
Gain on fair value remeasurement of contingent consideration		(2,914	)			—				(2,914	)			—
Income tax effect of above adjustments(1)		(17,245	)			(11,252	)			(62,880	)			(53,526	)
Total adjustments	$	55,983			$	32,227			$	185,617			$	175,125
Non-GAAP adjusted net income	$	68,519			$	64,167			$	254,807			$	223,280
Adjusted weighted-average shares — diluted(2)		40,109,649				41,279,982				40,424,180				41,788,125
Adjusted earnings per share(2)	$	1.77			$	1.58			$	6.45			$	5.47

(1)  The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended December 31, 2024 and 2023 were 25.3% and 25.9%, respectively; and the blended federal and state statutory rate for the years ended December 31, 2024 and 2023 were 26.5% and 25.9%, respectively. As such, the non-GAAP effective tax rates for the three months ended December 31, 2024 and 2023 were 23.5% and 25.9%, respectively; and the non-GAAP effective tax rates for the years ended December 31, 2024 and 2023 were 25.3% and 23.4%, respectively.
(2)  Adjusted weighted-average shares - diluted were calculated using the “if-converted” method for our convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense added-back to non-GAAP adjusted net income. For the three months ended December 31, 2024 and 2023, adjusted weighted-average shares – diluted includes 6,606,305 and 7,509,104 shares, respectively, attributable to our convertible notes. For the years ended December 31, 2024 and 2023, adjusted weighted-average shares – diluted includes 6,606,305 and 6,793,421 shares, respectively, attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive.

FAQ

What was Collegium's (COLL) revenue growth in Q4 2024?

Collegium's Q4 2024 revenue grew 22% year-over-year to $181.9 million, setting a new quarterly record.

How much did Collegium (COLL) spend on share repurchases in 2024?

Collegium spent $60 million on share repurchases in 2024, including $25 million in Q4 and $35 million through an accelerated program in May.

What was Jornay PM's performance for Collegium (COLL) in 2024?

Jornay PM achieved $100.7 million in pro forma full-year revenue, with prescriptions growing 29% year-over-year in Q4 2024.

How did Belbuca and Xtampza ER perform for Collegium (COLL) in Q4 2024?

Belbuca revenue reached $55.2 million (up 12% YoY) and Xtampza ER revenue was $51.5 million (up 6% YoY), both setting quarterly records.

What was Collegium's (COLL) adjusted EBITDA for full-year 2024?

Collegium's full-year 2024 adjusted EBITDA was $401.2 million, representing a 9% increase from 2023.